Our global state-of-the-art laboratories based in Craigavon, UK and Durham NC, USA, alongside our partnership lab in Shanghai, China are ready to operate both research-use-only and clinical trial diagnostic assays. We offer a full range of Clinical Trial Solutions for our clients. Our Lab locations and contact details can be found here.
We have fully automated processing in place and a full laboratory information management system (LIMS), which tracks samples from receipt to the completion of your study.
We also offer a range of Supporting Lab Services, from sample sourcing and tissue processing to immunohistochemistry, pathology review and digital pathology slide scanning and storage. You can also make use of any of these services in a fee-for-service manner for routine genomic research. Contact us if you are interested in working with Almac Diagnostic Services for these laboratory services.
We already offer clients a wide range of Platforms and Technologies but will adopt additional technologies as required. We currently offer clients both Almac DNA panel and RNA panel solutions for clinical trials. These panels, based on Illumina chemistry and technology, offer a comprehensive solution for multi-arm clinical trials, allowing dual extraction from one FFPE sample, saving precious tissue, time and costs in the process.
Almac has over ten years’ RNA profiling experience and has processed tens of thousands of samples for gene expression analysis using a range of tissue types including peripheral blood, bone marrow, sputum, CSF and solid tissue.
Our specific area of expertise is working with degraded RNA from FFPE samples. This difficult sample type is used routinely in our labs for both biomarker discovery and routine clinical testing. Our research and diagnostic systems handle a range of complexity and processing rates, from low to extremely high.
Through our expertise we’ve developed our own range of biomarker discovery tools; the Xcel Array and Cancer DSA Arrays, which are microarray-based tools optimised for biomarker research in FFPE tissue. We have developed specialist skills in working with FFPE in qPCR & NGS platforms. We have used these tools extensively for both biomarker discovery and development and in the delivery of clinical assays in routine testing.
From Traditional Sanger Sequencing to Next Generation Sequencing
We offer qPCR services for DNA analysis and array-based systems such as the Affymetrix DMET™, Oncoscan®, Cytoscan® and routine SNP arrays. All of our DNA analysis services can be utilised in both a research and a diagnostics manner. The platforms we use for DNA analysis are suitable for diagnostic delivery and we have a number of CLIA validated assays available, such as the Cobas® KRAS, BRAF and EGFR.
We have also developed our own CLIA validated next generation sequencing assay for the P53 oncogene. This test has been developed in collaboration with Illumina and is delivered on the Illumina MiSeq platform from our CLIA/CAP lab.